Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7266151 | 1.00 | NOS2 (0.31) | NOS2RECQLPOLBALDH1A1TP53 | |
| SCHEMBL6585663 | 0.77 | CTSK (0.40) | POLBHPGD | |
| SCHEMBL6584546 | 0.76 | SLC6A2 (0.35) | — | |
| SCHEMBL6585188 | 0.76 | CPN1 (0.34) | — | |
| SCHEMBL6584313 | 0.74 | DPP4 (0.37) | — | |
| SCHEMBL6586715 | 0.73 | CA2 (0.38) | HPGD | |
| SCHEMBL6586743 | 0.72 | CPN1 (0.32) | — | |
| SCHEMBL6585899 | 0.71 | SLC6A3 (0.43) | TP53 | |
| SCHEMBL6586012 | 0.71 | SMYD3 (0.32) | — | |
| SCHEMBL7839828 | 0.69 | OPRD1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362857-B1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | DAINIPPON PHARMACEUTICAL CO (JP) | 2004-08-11 | — | — | EP | claimed |
| US-20030216433-A1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1362857-A1 | (S)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinymethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-11-19 | — | — | EP | claimed |
| EP-1362857-B1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | DAINIPPON PHARMACEUTICAL CO (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-6696468-B2 | GASTROINTESTINAL MOTILITY ENHANCER OR PROKINETIC AGENT; AFFINITY FOR 5-HT4 RECEPTOR; REDUCED SIDE EFFECTS TO HEART OR CENTRAL NERVOUS SYSTEM | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| WO-2003097638-A1 | (S)-4-AMINO-5-CHLORO-2-METHOXY-N-[1-[1-(2-TETRAHYDROFURYLCARBONYL)-4-PIPERIDINYLMETHYL]-4-PIPERIDINYL]BENZAMIDE, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-27 | — | — | WO | disclosed |
| US-20030216433-A1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1362857-A1 | (S)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinymethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216433-A1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | GIPR, MLNR, HTR5A | NOS2 3055/4885RECQL 4527/4885POLB 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.